NO20075562L - Anvendelse av selektive klorid kanal modulatorer for behandling av alkohol og/eller medikament misbruk - Google Patents

Anvendelse av selektive klorid kanal modulatorer for behandling av alkohol og/eller medikament misbruk

Info

Publication number
NO20075562L
NO20075562L NO20075562A NO20075562A NO20075562L NO 20075562 L NO20075562 L NO 20075562L NO 20075562 A NO20075562 A NO 20075562A NO 20075562 A NO20075562 A NO 20075562A NO 20075562 L NO20075562 L NO 20075562L
Authority
NO
Norway
Prior art keywords
alcohol
chloride channel
relates
treatment
drug abuse
Prior art date
Application number
NO20075562A
Other languages
English (en)
Norwegian (no)
Inventor
Sanjay Sabnani
Original Assignee
Hythiam Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hythiam Inc filed Critical Hythiam Inc
Publication of NO20075562L publication Critical patent/NO20075562L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20075562A 2005-04-21 2007-11-05 Anvendelse av selektive klorid kanal modulatorer for behandling av alkohol og/eller medikament misbruk NO20075562L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/111,435 US20050192271A1 (en) 2003-07-15 2005-04-21 Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
PCT/US2006/013155 WO2006115743A2 (en) 2005-04-21 2006-04-07 Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse

Publications (1)

Publication Number Publication Date
NO20075562L true NO20075562L (no) 2007-12-07

Family

ID=37215204

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075562A NO20075562L (no) 2005-04-21 2007-11-05 Anvendelse av selektive klorid kanal modulatorer for behandling av alkohol og/eller medikament misbruk

Country Status (17)

Country Link
US (3) US20050192271A1 (es)
EP (1) EP1742639B1 (es)
JP (1) JP2008536921A (es)
KR (1) KR20080004615A (es)
CN (1) CN101203225A (es)
AT (1) ATE539755T1 (es)
AU (1) AU2006240324B2 (es)
BR (1) BRPI0610038A2 (es)
CA (1) CA2605918A1 (es)
CR (1) CR9444A (es)
IL (1) IL186641A0 (es)
MX (1) MX2007012993A (es)
NO (1) NO20075562L (es)
NZ (1) NZ562585A (es)
RU (1) RU2007143053A (es)
WO (1) WO2006115743A2 (es)
ZA (1) ZA200709048B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050192271A1 (en) * 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
RU2468799C1 (ru) * 2011-08-03 2012-12-10 Общество с ограниченной ответственностью "Урал Крафт" Способ купирования алкогольного абстинентного синдрома посредством блокады бензодиазепиновых рецепторов
WO2015054730A1 (en) * 2013-10-14 2015-04-23 Palmaya Pty Ltd Compositions and methods of administering same
US20200143922A1 (en) * 2016-06-03 2020-05-07 Yale University Methods and apparatus for predicting depression treatment outcomes
JP2021521103A (ja) * 2018-04-06 2021-08-26 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 物質使用障害の処置におけるガボキサドールの使用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028611A (en) * 1989-06-29 1991-07-02 The Regents Of The University Of Minnesota Treatment for cocaine use
US5519017A (en) * 1990-03-29 1996-05-21 Lts Lohmann Therapie-Systeme Gmbh + Co. Kg Pharmaceutic formulation for the treatment of alcoholism
SE9100860D0 (sv) * 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use
DE4123106A1 (de) * 1991-07-09 1993-01-14 Schering Ag Arzneimittel zur behandlung von entzugssymptomen
US5229120A (en) * 1992-02-05 1993-07-20 Devincent James F Treatment for cocaine abuse
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
GB9420010D0 (en) * 1994-10-01 1994-11-16 Marck Sharp & Dohme Limited Nucleic acids
ID26346A (id) * 1998-03-31 2000-12-14 Shionogi & Co PROSES PEMBUATAN TURUNAN ASAM 5-HIDROKSIBENZO (b)TIOFEN-3-KARBOKSILAT
AU4100699A (en) 1998-05-28 1999-12-13 Sepracor, Inc. Compositions and methods employing r(-) fluoxetine and other active ingredients
US6890951B2 (en) * 1998-08-05 2005-05-10 Brookhaven Science Associates Llc Treatment of addiction and addiction-related behavior
US6541520B1 (en) * 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
US6339106B1 (en) * 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
EP1133299A1 (en) * 1998-11-23 2001-09-19 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
US6489341B1 (en) * 1999-06-02 2002-12-03 Sepracor Inc. Methods for the treatment of neuroleptic and related disorders using sertindole derivatives
US6399826B1 (en) * 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US6750235B1 (en) * 1999-09-30 2004-06-15 The General Hospital Corporation Pramipexole as a treatment for cocaine craving
EP1125579A3 (en) * 2000-01-18 2003-01-02 Pfizer Products Inc. Uses of agrp-melanocortin receptor binding modulating compounds
KR100712570B1 (ko) * 2001-01-17 2007-05-02 하이디엄, 인크. 알콜 의존성 치료약의 제조에서 플루마제닐의 용도
US20050192271A1 (en) * 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
CA2436511C (en) * 2001-02-15 2009-08-04 Juan Jose Legarda Ibanez Use of flumazenil to produce a medicament for the treatment of cocaine dependency
US20020150632A1 (en) * 2001-04-12 2002-10-17 Nick Scott Psychonutracological method for craving reduction in humans
FR2827172B1 (fr) * 2001-07-13 2004-07-02 Pf Medicament Derives de pyridin-2-yl-methylamine pour le traitement de la dependance aux opioides
US20030176456A1 (en) * 2001-12-21 2003-09-18 June Harry L. Methods for reducing alcohol cravings in chronic alcoholics
US6740677B2 (en) * 2002-08-19 2004-05-25 Hong Xue Methods of treating benzodiazepine site (BZD-S) associated syndromes using 2′ hydroxyflavonoids
AU2004216360B2 (en) * 2003-02-27 2009-09-17 Eisai R & D Management Co., Ltd. Pharmaceutical composition for treatment of drug dependence
CA2526101A1 (en) * 2003-05-30 2004-12-23 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of nalmefene
JP2005332453A (ja) * 2004-05-19 2005-12-02 Hitachi Ltd 情報再生装置及び情報再生方法
US20060167723A1 (en) * 2005-01-21 2006-07-27 Berg L M Method of treating dependencies
JP2008538748A (ja) 2005-04-07 2008-11-06 ハイシアム， インコーポレイテッド 不安、物質乱用及び依存の予防のための改良型方法及び組成物

Also Published As

Publication number Publication date
EP1742639A2 (en) 2007-01-17
AU2006240324B2 (en) 2010-02-25
MX2007012993A (es) 2008-03-11
CA2605918A1 (en) 2006-11-02
NZ562585A (en) 2010-04-30
EP1742639A4 (en) 2008-05-07
CR9444A (es) 2008-02-20
US20050192271A1 (en) 2005-09-01
WO2006115743A3 (en) 2007-06-28
US20090215751A1 (en) 2009-08-27
US7863267B2 (en) 2011-01-04
CN101203225A (zh) 2008-06-18
US20080207599A1 (en) 2008-08-28
ZA200709048B (en) 2008-09-25
BRPI0610038A2 (pt) 2016-11-29
AU2006240324A1 (en) 2006-11-02
JP2008536921A (ja) 2008-09-11
RU2007143053A (ru) 2009-05-27
EP1742639B1 (en) 2012-01-04
KR20080004615A (ko) 2008-01-09
ATE539755T1 (de) 2012-01-15
WO2006115743A2 (en) 2006-11-02
IL186641A0 (en) 2008-06-05

Similar Documents

Publication Publication Date Title
BRPI0607402A2 (pt) uso de inibidores de pde7 para o tratamento de dor neuropática
UA115131C2 (uk) Сполуки боронатного ефіру і його фармацевтичні рецептури
EA200901308A1 (ru) Ингибиторы белка, активирующего 5-липоксигеназу (flap)
NO20081838L (no) 5-lipoksygenaseaktiverende protein-(FLAP)-inhibitorer
DK1651161T3 (da) Farmaceutiske præparater og fremgangsmåder til at fremme sårheling
NO20090157L (no) Tienpyrimidiner anvendelige som modulatorer av ionekanaler
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA200501702A1 (ru) Устойчивая к манипуляциям дозировочная форма для трансдермального введения
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
EA200801164A3 (ru) Ингибиторы протеина, активирующего 5-липоксигеназу (flap)
EA200800356A1 (ru) Лечение ингибиторами абсорбции холестерина на основе азетидинона и омега-3 жирными кислотами и их комбинированным препаратом
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
EA201290138A1 (ru) Производные пиразола как модуляторы кальциевых каналов, активируемых высвобождением кальция
EA200971053A1 (ru) Способы лечения кожных язв
NO20064584L (no) Tetrahydropyridoindolderivater
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
EA201001288A1 (ru) Лечение гипертонии 25-гидроксивитамином d3
NO20084542L (no) Farmasoytisk kombinasjon inneholdende 3-(3-dimetylamino-1-etyl-2-metyl-propyl)-fenol og paracetamol
NO20075562L (no) Anvendelse av selektive klorid kanal modulatorer for behandling av alkohol og/eller medikament misbruk
CR8850A (es) Composicion y metodo para tratar hemorroides y/o transtornos ano-rectales
ATE410424T1 (de) Spirocyclische cyclohexan-derivate
EA200870089A1 (ru) Применение производных бензоконденсированного гетероциклического сульфамида для лечения злоупотребления психоактивным веществом и аддикции
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application